Coronavirus News Roundup: Upcoming MJH COVID-19 Coalition Event, Vaccine May Be Ready for FDA Submission by November
Here's the coronavirus-related news from this week that you should know.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), has infected an estimated 39,068,667 individuals worldwide at publishing time, and nearly 8 million Americans. The latest COVID-19 related news includes the upcoming MJH Life Sciences’ COVID-19 Coalition event, “Race for a Vaccine: The Latest Updates in COVID-19 Prevention”, and Pfizer’s expectations to submit its COVID-19 vaccine for emergency use authorization (EUA) to the FDA by late November.
Here’s a roundup of the latest coronavirus-related news:
Don’t Miss MJH Life Sciences’ latest COVID-19 Coalition Event
As investigators worldwide race to develop a safe and effective vaccine against COVID-19, other teams are working to explore additional means of prevention against the SARS-CoV-2 virus.
The next COVID-19 Coalition event takes place on Tuesday, October 27 at 6 PM ET.
Pfizer, BioNTech COVID-19 Vaccine May Be Ready for FDA Submission by Late November
Study results for Pfizer’s investigational COVID-19 vaccine could be ready by the end of November to support filing for US Emergency Use Authorization. BNT162, which is being developed by Pfizer in partnership with BioNTech, is a mRNA-based vaccine.
NIH Study Aims to Identify Most Promising Treatments for COVID-19
A new National Health of Institutes (NIH) study aims to determine which investigational COVID-19 treatments have the most potential to warrant advancement into larger clinical trials.
Long-Acting Antibody Combination Heads to Phase 3 Trials for COVID-19
AstraZeneca’s investigational long-acting antibody combination will advance into phase 3 clinical trials for COVID-19.
Pharmacists Garner Priority COVID-19 Vaccination in New Recommendations
The new National Academies of Sciences, Engineering, and Medicine's COVID-19 vaccine recommendations identify pharmacists as one of the essential groups that should be the first to receive the vaccines when they are available.
Examining Impact of COVID-19 Diagnosis Timing on AF Progression | AHA 2024
November 21st 2024“[O]ur data do not support the hypothesis that early COVID resulted in more significant structural or electrical cardiac remodeling that would increase the likelihood of atrial fibrillation progression,” the authors said.
